Clarivate in the news
Global information services provider
Tamtam found 12 recent articles about Clarivate.
- Clarivate (NYSE:CLVT) Stock Jumps 4.4% - Time to Buy?
Clarivate's stock price increased by 4.4% despite mixed analyst ratings and a slight revenue decrease, while insider trading and institutional investment activity were notable.
- Clarivate Completes $600 Million Healthcare Business Sale to Altaris
Clarivate sold its Life Sciences & Healthcare business to Altaris for $600 million to reduce debt and focus on academic research and intellectual property services.
- Clarivate Completes $600 Million Sale Of Life Sciences & Healthcare Segment To Altaris
Clarivate completed the $600 million sale of its Life Sciences & Healthcare segment to Altaris to simplify its portfolio, strengthen its balance sheet, and focus on its Academia & Government and Intellectual Property segments.
- Altaris completes carve-out of Clarivate’s life sciences and healthcare business
Altaris acquired Clarivate's Life Sciences & Healthcare business, which will operate independently under CEO Henry Levy, providing AI-enabled data intelligence to the life sciences sector.
- Altaris Completes Acquisition of Clarivate’s Life Sciences & Healthcare Business
Altaris acquired Clarivate's Life Sciences & Healthcare business, an AI-enabled data intelligence platform for the pharmaceutical, biotechnology, and medical technology industries.
- Clarivate Completes $600 Million Sale of Life Sciences & Healthcare Segment
Clarivate completed the $600 million sale of its Life Sciences & Healthcare segment to Astorg.
- Clarivate completes $600m life sciences unit sale to Altaris
Clarivate sold its Life Sciences & Healthcare segment to Altaris, LLC for $600 million to reduce debt and focus on Academia & Government and Intellectual Property segments.
- Clarivate Completes Sale of Life Sciences & Healthcare Segment, Advances Strategic Transformation
Clarivate completed the sale of its Life Sciences & Healthcare segment for $600 million to Altaris, LLC, focusing on its core Academia & Government and Intellectual Property segments and using the proceeds to reduce debt.
- Svetlana Mojsov is named a citation laureate by Clarivate
Svetlana Mojsov has been named a 2026 Citation Laureate by Clarivate for her GLP-1 research, which contributed to diabetes and obesity treatments.
- Clarivate Report Assesses Libraries’ Adoption, Implementation of AI
Clarivate's latest report reveals varied AI adoption in libraries globally, with cautious growth in the US and faster implementation in Asia, highlighting shifting concerns toward trust and ethics.
- Clarivate Announces Final Results of Offer to Purchase for Cash Certain of its Outstanding Debt Securities
Clarivate completed its cash tender offer to repurchase up to $75 million of its 3.875% Senior Secured Notes due 2028.
- Clarivate names 22 Citation Laureates for 2026
Clarivate recognized 22 researchers as Citation Laureates for 2026, acknowledging their highly cited work that may be of Nobel class.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Clarivate?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies